Emyria opens Empax Centre to target care gaps in resistant PTSD
April 10, 2024 at 02:01 pm EDT
Share
(via NewsDirect)
Emyria Ltd (ASX:EMD) CEO Michael Winlo sits down with Proactive’s Jonathan Jackson to discuss significant advancements in the company's mental health initiatives. Emyria recently opened the Empax Centre, a cutting-edge facility aimed at enhancing mental health treatments, including MDMA-assisted therapy for PTSD. Emyria’s ambitious vision is showcased by this centre, targeting care gaps in resistant PTSD, with sights set on operational profitability and global expansion. Winlo discusses how the technology employed at the Empax Centre enhances patient care as well as Emyria’s plans to broaden its therapeutic offerings. Significant progress has also been made with the expansion of Emyria’s authorised prescriber team. The addition of a second psychiatrist as an authorised prescriber underlines Emyria’s commitment to advancing mental health care, aligning with its expansion efforts. Emyria is also collaborating with charity Reach Wellness and this partnership signifies a strategic step towards validating Emyria’s MDMA-assisted therapy model, aiming to improve PTSD treatment for first responders. This collaboration, backed by significant fundraising, is pivotal for demonstrating the model’s safety, effectiveness and scalability.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source Press Releases
Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.
EMYRIA LIMITED 
